Login to Your Account

GSK Spinout Autifony Brings in $16.4M for Hearing Loss Therapy

By Nuala Moran

Wednesday, August 24, 2011
LONDON – The latest spin-out to emerge from GlaxoSmithKline (GSK) plc's restructuring has raised £10 million (US$16.4 million) from venture capital (VC) investors to fund the development of drug treatments for hearing loss and tinnitus. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription